Child death from MIS-C, rare disease linked to Covid-19 – first such death in LA County


LOS ANGELES (KABC) – A child treated at Children’s Hospital Los Angeles died of multisystem inflammatory syndrome linked to a coronavirus known as MIS-C, the first such death in LA County.

The patient had a “pre-existing cardiac condition” and died of complications associated with MIS-C, according to a statement from CHLA Public Relations Officer Lure Ren Song.

Further details about the patient were not released.

The medical center has treated 32 patients with MIS-C ranging in age from 4 months to 17 years, the statement added. Thirty of them have been successfully treated and discharged.

Clock: A local doctor explains the rare condition in children connected to COVID-19

“If parents think their child has MIS-C, it is important that they contact their child’s doctor or pediatrician immediately.” Song said.

U.S. Department of Disease Control and Prevention According to the centers, about two dozen children across the country have died from the syndrome, in about 1,300 reported cases. In late October, Los Angeles County health officials reported a total of 43 known cases locally.

CDC Also noted is the fact that children and adolescents “after Covid-1 illness or after contact with someone with Covid-1.” It is associated with the syndrome. ” It’s still unclear what causes some children to develop the syndrome, while others with coronavirus illness or contacts don’t.

According to the CDC, the average age of MIS-C patients is 8, but the cases include patients older than 20 years. Nationally, more than 75% of cases are of Latino or Black children. In infected children, 99% tested positive for the virus that causes COVID-19, while another 1% interacted with a COVID patient.

MIS-C can result in inflammation of body parts including the heart, lungs, kidneys, brain, skin, eyes and gastrointestinal organs, potentially affecting lifelong health.

The City News Service contributed to this report.

Copyright Pirate 20 2020 KABC-TV. All rights reserved to us.

.